Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPNASDAQ:APRENASDAQ:KPRXNYSE:PTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.39-1.5%$0.38$0.30▼$3.33$9.11M-1.37166,924 shs168,216 shsAPREAprea Therapeutics$1.73+0.6%$1.72$1.41▼$5.01$9.57M1.1822,255 shs17,859 shsKPRXKiora Pharmaceuticals$3.00+1.4%$3.01$2.51▼$5.55$9.13M-0.6730,800 shs9,961 shsPTNPalatin Technologies$0.09-44.6%$0.00$0.09▼$2.48$2.45M0.942.28 million shs14.57 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-1.52%-5.60%-7.40%-43.44%-84.54%APREAprea Therapeutics+0.58%+8.12%-1.14%-30.80%-65.19%KPRXKiora Pharmaceuticals+1.35%-3.69%-9.09%-10.45%-37.87%PTNPalatin Technologies0.00%0.00%-55.19%+9,409,900.00%+9,409,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.1404 of 5 stars3.53.00.00.02.61.70.0APREAprea Therapeutics3.4818 of 5 stars3.54.00.00.03.22.51.3KPRXKiora Pharmaceuticals3.351 of 5 stars3.85.00.00.02.91.70.6PTNPalatin TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.001,961.86% UpsideAPREAprea Therapeutics 3.00Buy$15.50795.95% UpsideKPRXKiora Pharmaceuticals 3.50Strong Buy$10.00233.33% UpsidePTNPalatin Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PTN, ACXP, KPRX, and APRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.003/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.003/19/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/AAPREAprea Therapeutics$580K16.50N/AN/A$4.54 per share0.38KPRXKiora Pharmaceuticals$16M0.57N/AN/A$7.14 per share0.42PTNPalatin Technologies$350K6.99N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$0.70N/AN/AN/AN/A-392.36%-223.78%8/8/2025 (Estimated)APREAprea Therapeutics-$14.29M-$2.37N/AN/AN/A-1,029.50%-57.86%-47.94%8/11/2025 (Estimated)KPRXKiora Pharmaceuticals-$12.51M-$2.90N/AN/AN/AN/A21.32%16.39%8/8/2025 (Estimated)PTNPalatin TechnologiesN/A-$1.55N/A∞N/AN/AN/AN/AN/ALatest PTN, ACXP, KPRX, and APRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/A5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A3/25/2025Q4 2024APREAprea Therapeutics-$0.69-$0.49+$0.20-$0.49$0.15 million$0.21 million3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 million3/17/2025Q4 2024ACXPAcurx Pharmaceuticals-$0.18-$0.16+$0.02-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.801.80APREAprea TherapeuticsN/A7.287.28KPRXKiora PharmaceuticalsN/A8.978.97PTNPalatin TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%APREAprea Therapeutics34.19%KPRXKiora Pharmaceuticals76.97%PTNPalatin Technologies11.50%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals29.60%APREAprea Therapeutics12.80%KPRXKiora Pharmaceuticals0.05%PTNPalatin Technologies7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals323.48 million11.99 millionOptionableAPREAprea Therapeutics75.53 million4.74 millionNo DataKPRXKiora Pharmaceuticals103.04 million2.97 millionNot OptionablePTNPalatin Technologies3026.01 millionN/AN/APTN, ACXP, KPRX, and APRE HeadlinesRecent News About These CompaniesStockNews.com Initiates Coverage on Palatin Technologies (NYSE:PTN)May 22, 2025 | americanbankingnews.comPalatin Technologies, Inc. (PTN) Q3 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comPalatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...May 15, 2025 | gurufocus.comQ3 2025 Palatin Technologies Inc Earnings Call TranscriptMay 15, 2025 | gurufocus.comPalatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug DevelopmentMay 9, 2025 | nasdaq.comPalatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025May 9, 2025 | prnewswire.comPalatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma TreatmentMay 7, 2025 | nasdaq.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7, 2025 | in.investing.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7, 2025 | in.investing.comNYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)May 7, 2025 | businesswire.comPalatin Expects $11.5 Million Financing to Cure NYSE American Delisting NoticeMay 7, 2025 | prnewswire.comPalatin Technologies Announces Pricing of up to $23 Million Public OfferingMay 7, 2025 | prnewswire.comPalatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma TherapyMay 5, 2025 | prnewswire.comPL9643 shows promise in dry eye disease treatmentApril 30, 2025 | investing.comPalatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DEDApril 30, 2025 | nasdaq.comPalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye DiseaseApril 29, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTN, ACXP, KPRX, and APRE Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.39 -0.01 (-1.52%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.39 +0.00 (+0.26%) As of 05/28/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Aprea Therapeutics NASDAQ:APRE$1.73 +0.01 (+0.58%) Closing price 05/28/2025 03:47 PM EasternExtended Trading$1.72 0.00 (-0.29%) As of 05/28/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Kiora Pharmaceuticals NASDAQ:KPRX$3.00 +0.04 (+1.35%) Closing price 05/28/2025 03:54 PM EasternExtended Trading$3.16 +0.16 (+5.17%) As of 05/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Palatin Technologies NYSE:PTN$0.09 -0.08 (-44.65%) As of 05/7/2025Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
